Positive results from study of Symphony tCGM System (Echo Therapeutics) in critically ill patients

New results of needle-free Symphony Transdermal Continuous Glucose Monitoring (tCGM) System, from Echo Therapeutics, a non-invasive, wireless, transdermal continuous glucose monitoring system, collected from a clinical study of 15 critically ill patients over a 24 hour period at Tufts Medical Center in Boston, have been presented. Results show that using 570 Symphony tCGM glucose readings, paired with reference blood glucose measurements, the Mean Absolute Relative Difference was 12.3%.

In addition, a Clarke Error Grid (CEG) analysis showed that 81.7% of the readings appeared in the grid's A zone with the remaining 18.3% percent falling in the B zone. The grid's A zone represents results that are the most clinically accurate and results in the B zone are considered clinically acceptable. The Continuous Glucose-Error Grid analysis (CG-EGA) showed that 99.6% of the readings were clinically accurate (A) and 0.0% were benign (B) errors with a combined A+B of 99.6%. Finally, 94.4% of the calculated CGM rates were within +/-1 mg/dL/min of the reference rate and 99.6% were within +/-2 mg/dL/min. Data were presented at the Society of Critical Care Medicine's 42nd Critical Care Congress.